Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 4 1Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Lymphatic Metastasis 1

Interventions

pembrolizumab 43Specimen Handling 39Magnetic Resonance Spectroscopy 30Carboplatin 30Cyclophosphamide 27Biopsy 25Nivolumab 24Dexamethasone 22fludarabine 21Gemcitabine 19Bevacizumab 15atezolizumab 14Paclitaxel 14Temozolomide 13Pemetrexed 13Ipilimumab 13Docetaxel 13Cisplatin 13venetoclax 11Rituximab 11Prednisone 10X-Rays 9Lenalidomide 9Injections 9Fulvestrant 9lenvatinib 8Vincristine 8Trastuzumab 8Oxaliplatin 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × radium Ra 223 dichloride × 30 days × Clear all
NCT04071236 2026-06-05

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

NCT03317392 2026-05-20

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
132 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡